

Claes Held

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2108805/publications.pdf>

Version: 2024-02-01

226
papers

28,250
citations

20817

60
h-index

5394

164
g-index

238
all docs

238
docs citations

238
times ranked

26059
citing authors

#	ARTICLE	IF	CITATIONS
1	Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2009, 361, 1045-1057.	27.0	6,019
2	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1995-2008.	27.0	4,108
3	Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. <i>New England Journal of Medicine</i> , 2006, 354, 1567-1577.	27.0	1,536
4	Initial Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1395-1407.	27.0	1,508
5	Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2012, 366, 20-33.	27.0	701
6	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2021-2031.	27.0	641
7	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2009-2020.	27.0	526
8	Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2014, 370, 1702-1711.	27.0	467
9	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2011, 57, 672-684.	2.8	457
10	Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>Circulation</i> , 2011, 124, 544-554.	1.6	397
11	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet</i> , 2016, 387, 2302-2311.	13.7	389
12	Association Between Adoption of Evidence-Based Treatment and Survival for Patients With ST-Elevation Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1677.	7.4	356
13	Plasma Parathyroid Hormone and the Risk of Cardiovascular Mortality in the Community. <i>Circulation</i> , 2009, 119, 2765-2771.	1.6	351
14	Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study. <i>European Heart Journal</i> , 2013, 34, 3624-3631.	2.2	341
15	Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2011, 32, 2933-2944.	2.2	335
16	The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. <i>European Heart Journal</i> , 2016, 37, 1582-1590.	2.2	329
17	Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2141-2147.	2.8	308
18	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014, 35, 1864-1872.	2.2	303

#	ARTICLE	IF	CITATIONS
19	Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. <i>European Heart Journal</i> , 2017, 38, 3056-3065.	2.2	302
20	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2032-2043.	27.0	299
21	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019, 21, 665-675.	7.1	264
22	Ticagrelor in Patients with Stable Coronary Disease and Diabetes. <i>New England Journal of Medicine</i> , 2019, 381, 1309-1320.	27.0	255
23	Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. <i>New England Journal of Medicine</i> , 2017, 377, 1132-1142.	27.0	228
24	Effects of metoprolol vs verapamil in patients with stable angina pectoris: The Angina Prognosis Study in Stockholm (APSYS). <i>European Heart Journal</i> , 1996, 17, 76-81.	2.2	224
25	Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation. <i>Circulation</i> , 2013, 127, 2166-2176.	1.6	196
26	Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1689-1700.	2.8	186
27	Genetic Predisposition of the Interleukin-6 Response to Inflammation: Implications for a Variety of Major Diseases?. <i>Clinical Chemistry</i> , 2004, 50, 2136-2140.	3.2	185
28	Glucose Levels Predict Hospitalization for Congestive Heart Failure in Patients at High Cardiovascular Risk. <i>Circulation</i> , 2007, 115, 1371-1375.	1.6	180
29	Inflammatory Biomarkers Interleukin-6 and C-reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of) Tj ETQq1 1 0.784317 r gBT / Overlock	1.7	174
30	Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. <i>European Heart Journal</i> , 2017, 38, ehw525.	2.2	164
31	Prognostic implications of intima-media thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris. <i>European Heart Journal</i> , 2001, 22, 62-72.	2.2	157
32	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet</i> , 2019, 394, 1169-1180.	13.7	155
33	Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. <i>Blood</i> , 2014, 124, 3692-3698.	1.4	149
34	Regression of left ventricular hypertrophy in human hypertension with irbesartan. <i>Journal of Hypertension</i> , 2001, 19, 1167-1176.	0.5	148
35	Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2015, 36, 1264-1272.	2.2	144
36	Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity. <i>Circulation</i> , 2021, 144, 1024-1038.	1.6	140

#	ARTICLE	IF	CITATIONS
37	Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. <i>Platelets</i> , 2014, 25, 517-525.	2.3	138
38	Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. <i>European Heart Journal</i> , 2018, 39, 3766-3776.	2.2	112
39	Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T patients with coronary heart disease. <i>American Heart Journal</i> , 2010, 160, 655-661.e2.	2.7	111
40	Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: results of the INTERHEART study. <i>European Heart Journal</i> , 2012, 33, 452-466.	2.2	109
41	Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease. <i>European Heart Journal</i> , 2016, 37, 1993-2001.	2.2	101
42	Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization. <i>Circulation</i> , 2014, 129, 293-303.	1.6	100
43	Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. <i>Clinical Chemistry</i> , 2017, 63, 325-333.	3.2	97
44	Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 813-826.	2.8	95
45	Plasma parathyroid hormone and risk of congestive heart failure in the community. <i>European Journal of Heart Failure</i> , 2010, 12, 1186-1192.	7.1	92
46	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382	2.2	92
47	Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>American Heart Journal</i> , 2015, 169, 899-905.e1.	2.7	91
48	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. <i>Blood</i> , 2017, 129, 2980-2987.	1.4	85
49	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. <i>Circulation</i> , 2021, 143, 438-448.	1.6	85
50	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 534-543.	11.4	84
51	Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. <i>European Heart Journal</i> , 1999, 20, 1039-1043.	2.2	82
52	Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 645-653.	0.7	82
53	Platelet aggregability in vivo is attenuated by verapamil but not by metoprolol in patients with stable angina pectoris. <i>American Journal of Cardiology</i> , 1995, 75, 1-6.	1.6	80
54	Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1623-1630.	2.8	80

#	ARTICLE	IF	CITATIONS
55	Fibrinolytic Variables and Cardiovascular Prognosis in Patients With Stable Angina Pectoris Treated With Verapamil or Metoprolol. <i>Circulation</i> , 1997, 95, 2380-2386.	1.6	78
56	Prognostic value of plasma interleukin-6 concentrations and the $\hat{\sim}174\text{ G} > \text{C}$ and $\hat{\sim}572\text{ G} > \text{C}$ promoter polymorphisms of the interleukin-6 gene in patients with acute myocardial infarction treated with thrombolysis. <i>Atherosclerosis</i> , 2004, 174, 157-163.	0.8	74
57	Exercise capacity and muscle strength and risk of vascular disease and arrhythmia in 1.1 million young Swedish men: cohort study. <i>BMJ</i> , The, 2015, 351, h4543.	6.0	72
58	All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. <i>Heart</i> , 2016, 102, 926-933.	2.9	70
59	Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. <i>PLoS Medicine</i> , 2021, 18, e1003513.	8.4	70
60	Internet-Based Cognitive Behavioral Therapy for Symptoms of Depression and Anxiety Among Patients With a Recent Myocardial Infarction: The U-CARE Heart Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2018, 20, e88.	4.3	68
61	Physical activity in patients with stable coronary heart disease: an international perspective. <i>European Heart Journal</i> , 2013, 34, 3286-3293.	2.2	67
62	Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2135-2144.	2.8	66
63	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021, 42, 1742-1756.	2.2	63
64	Effects of Expanded Cardiac Rehabilitation on Psychosocial Status in Coronary Artery Disease with Focus on Type D Characteristics. <i>Journal of Behavioral Medicine</i> , 2007, 30, 253-261.	2.1	62
65	Evaluation of a web-based ECG-interpretation programme for undergraduate medical students. <i>BMC Medical Education</i> , 2008, 8, 25.	2.4	61
66	Prognostic implications of autonomic function assessed by analyses of catecholamines and heart rate variability in stable angina pectoris. <i>British Heart Journal</i> , 2002, 87, 415-422.	2.1	60
67	Activation of peripheral and in vivo transmigrated neutrophils in patients with stable coronary artery disease. <i>Atherosclerosis</i> , 2007, 192, 328-334.	0.8	60
68	Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 678-685.	1.8	60
69	Predicting two-year survival versus non-survival after first myocardial infarction using machine learning and Swedish national register data. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 99.	3.0	57
70	Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease. <i>Journal of Internal Medicine</i> , 2018, 283, 83-92.	6.0	57
71	Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2018, 3, 1160.	6.1	57
72	Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. <i>Atherosclerosis</i> , 2000, 148, 179-188.	0.8	55

#	ARTICLE	IF	CITATIONS
73	Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. <i>Journal of Internal Medicine</i> , 2007, 261, 472-479.	6.0	54
74	Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. <i>Heart</i> , 2017, 103, 623-628.	2.9	54
75	Effects of blood pressure and lipid lowering on cognition. <i>Neurology</i> , 2019, 92, e1435-e1446.	1.1	54
76	Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. <i>EuroIntervention</i> , 2015, 11, 737-745.	3.2	54
77	Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS). <i>Heart</i> , 2006, 92, 177-182.	2.9	51
78	Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other) Trial. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1000-1008.	3.7	51
79	Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1493-1499.	2.8	47
80	Predicting Adherence to Internet-Delivered Psychotherapy for Symptoms of Depression and Anxiety After Myocardial Infarction: Machine Learning Insights From the U-CARE Heart Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2018, 20, e10754.	4.3	47
81	Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: The Heart Outcomes Prevention Evaluation (HOPE)-2 trial. <i>Canadian Journal of Cardiology</i> , 2006, 22, 47-53.	1.7	46
82	Long-term effects of an expanded cardiac rehabilitation programme after myocardial infarction or coronary artery bypass surgery: a five-year follow-up of a randomized controlled study. <i>Clinical Rehabilitation</i> , 2011, 25, 79-87.	2.2	46
83	Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. <i>European Heart Journal</i> , 2014, 35, 969-978.	2.2	46
84	Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. <i>European Heart Journal</i> , 2017, 38, 2813-2822.	2.2	45
85	Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). <i>American Heart Journal</i> , 2014, 168, 588-596.	2.7	44
86	Lipoprotein-associated Phospholipase A ₂ Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	44
87	Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. <i>JAMA Cardiology</i> , 2021, 6, 1440.	6.1	43
88	Dose-Response Relationship of Total and Leisure Time Physical Activity to Risk of Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 701-708.	3.9	41
89	Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 771-778.	1.8	41
90	Haemostatic markers, inflammatory parameters and lipids in male and female patients in the Angina Prognosis Study In Stockholm (APSIS). A comparison with healthy controls. <i>Journal of Internal Medicine</i> , 1997, 241, 59-69.	6.0	40

#	ARTICLE	IF	CITATIONS
91	Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1048-1057.	2.8	40
92	Factors associated with emotional distress in patients with myocardial infarction: Results from the SWEDEHEART registry. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 910-920.	1.8	40
93	Tooth loss is independently associated with poor outcomes in stable coronary heart disease. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 839-846.	1.8	39
94	Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. <i>Heart</i> , 2014, 100, 1762-1769.	2.9	38
95	Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2016, 202, 589-594.	1.7	38
96	Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA{middle dot}CER) trial. <i>European Heart Journal</i> , 2013, 34, 1723-1731.	2.2	36
97	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. <i>American Heart Journal</i> , 2017, 186, 91-99.	2.7	36
98	The 2011 outcome from the Swedish Health Care Registry on Heart Disease (SWEDEHEART). <i>Scandinavian Cardiovascular Journal</i> , 2013, 47, 1-10.	1.2	35
99	Genetic and Environmental Influences on the Plasma Interleukin-6 Concentration in Patients with a Recent Myocardial Infarction: A Caseâ€“Control Study. <i>Journal of Interferon and Cytokine Research</i> , 2011, 31, 259-264.	1.2	34
100	Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2018, 138, 1666-1676.	1.6	34
101	Prediction of Residual Risk by Ceramideâ€“Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy. <i>Journal of the American Heart Association</i> , 2020, 9, e015258.	3.7	34
102	An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. <i>American Heart Journal</i> , 2017, 187, 53-61.	2.7	33
103	Cardiac rehabilitation after acute myocardial infarction in Sweden â€“ evaluation of programme characteristics and adherence to European guidelines: The Perfect Cardiac Rehabilitation (Perfect-CR) study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 18-27.	1.8	33
104	Venous thromboembolism in association with features of the metabolic syndrome. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2007, 100, 679-684.	0.5	31
105	Do clinical factors explain persistent sex disparities in the use of acute reperfusion therapy in STEMI in Sweden and Canada?. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013, 2, 350-358.	1.0	31
106	Treatment Activity, User Satisfaction, and Experienced Usability of Internet-Based Cognitive Behavioral Therapy for Adults With Depression and Anxiety After a Myocardial Infarction: Mixed-Methods Study. <i>Journal of Medical Internet Research</i> , 2018, 20, e87.	4.3	31
107	Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART). <i>Vascular Medicine</i> , 2008, 13, 245-253.	1.5	30
108	Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 154.	1.6	30

#	ARTICLE	IF	CITATIONS
109	Soluble cell adhesion molecules in hypertensive concentric left ventricular hypertrophy. <i>Journal of Hypertension</i> , 2002, 20, 1563-1569.	0.5	29
110	Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2019, 8, e010641.	3.7	29
111	Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: Insights from the PLATElet inhibition and patient outcomes (PLATO) trial. <i>American Heart Journal</i> , 2013, 166, 474-480.	2.7	28
112	Impact of Selection Bias on Estimation of Subsequent Event Risk. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	28
113	Prognostic implications of results from exercise testing in patients with chronic stable angina pectoris treated with metoprolol or verapamil. A report from The Angina Prognosis Study In Stockholm (APSIS). <i>European Heart Journal</i> , 2000, 21, 901-910.	2.2	26
114	Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. <i>American Heart Journal</i> , 2017, 187, 194-203.	2.7	26
115	SWEDHEART Annual Report 2012. <i>Scandinavian Cardiovascular Journal</i> , 2014, 48, 1-1.	1.2	25
116	Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 856-864.	2.9	25
117	Effects of an expanded cardiac rehabilitation programme in patients treated for an acute myocardial infarction or a coronary artery by-pass graft operation. <i>Clinical Rehabilitation</i> , 2008, 22, 306-318.	2.2	24
118	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. <i>Canadian Journal of Cardiology</i> , 2016, 32, 311-318.	1.7	24
119	Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 805-819.	2.9	24
120	Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. <i>Clinical Cardiology</i> , 2019, 42, 498-505.	1.8	24
121	Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. <i>Circulation</i> , 2020, 141, 10-20.	1.6	24
122	Persistent emotional distress after a first-time myocardial infarction and its association to late cardiovascular and non-cardiovascular mortality. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1510-1518.	1.8	23
123	Effects of revascularization within 14 days of hospital admission due to acute coronary syndrome on 1-year mortality in patients with previous coronary artery bypass graft surgery. <i>European Heart Journal</i> , 2007, 28, 316-325.	2.2	22
124	Magnitude of Troponin Elevation and Long-Term Clinical Outcomes in Acute Coronary Syndrome Patients Treated With and Without Revascularization. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002314.	3.9	22
125	Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2016, 1, 73.	6.1	22
126	Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by) Tj ETQq0 0 0.rgBT /Overlock 10 T		

#	ARTICLE	IF	CITATIONS
127	Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. <i>International Journal of Cardiology</i> , 2017, 245, 271-276.	1.7	22
128	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002471.	3.6	22
129	Fifteen Challenges in Establishing a Multidisciplinary Research Program on eHealth Research in a University Setting: A Case Study. <i>Journal of Medical Internet Research</i> , 2017, 19, e173.	4.3	22
130	Prognostic implications of ambulatory myocardial ischemia and arrhythmias and relations to ischemia on exercise in chronic stable angina pectoris (the Angina Prognosis Study In Stockholm) <i>Tj ETQq0 0 0 rgBT. Overlock 110 Tf 50</i>		
131	Vorapaxar with or without clopidogrel after non-â€“ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial. <i>American Heart Journal</i> , 2014, 168, 869-877.e1.	2.7	21
132	Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2020, 221, 1-8.	2.7	19
133	Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease â€“ A STABILITY Substudy. <i>Journal of the American Heart Association</i> , 2022, 11, e023667.	3.7	19
134	Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2014, 168, 68-75.e2.	2.7	18
135	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019, 139, 863-873.	1.6	18
136	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. <i>European Heart Journal</i> , 2021, 42, 2995-3007.	2.2	18
137	Prognosis of patients with stable angina pectoris on antianginal drug therapy. <i>American Journal of Cardiology</i> , 1996, 77, 6D-15D.	1.6	17
138	Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non-â€“ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2014, 113, 936-944.	1.6	17
139	Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-â€“ST-Segment Elevation Acute Coronary Syndromes (from the) <i>Tj ETQq1 1 0 784314 rgBT /Ov</i>		
140	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002470.	3.6	17
141	Invasive strategies and outcomes for non-ST-segment elevation acute coronary syndromes: a twelve-year experience from SWEDEHEART. <i>EuroIntervention</i> , 2016, 12, 1108-1116.	3.2	17
142	Cardiovascular prognosis in relation to apolipoproteins and other lipid parameters in patients with stable angina pectoris treated with verapamil or metoprolol. <i>Atherosclerosis</i> , 1997, 135, 109-118.	0.8	16
143	Ischaemia during exercise and ambulatory monitoring in patients with stable angina pectoris and healthy controls. Gender differences and relationships to catecholamines. <i>European Heart Journal</i> , 1998, 19, 578-587.	2.2	16
144	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2016, 175, 175-183.	2.7	16

#	ARTICLE	IF	CITATIONS
145	Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. <i>Kidney International</i> , 2017, 91, 216-226.	5.2	16
146	Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. <i>American Heart Journal</i> , 2016, 178, 1-8.	2.7	15
147	When do we need clinical endpoint adjudication in clinical trials?. <i>Uppsala Journal of Medical Sciences</i> , 2019, 124, 42-45.	0.9	15
148	Attending Heart School and long-term outcome after myocardial infarction: A decennial SWEDEHEART registry study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 145-154.	1.8	15
149	Clinical Frailty Scale classes are independently associated with 6-month mortality for patients after acute myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 89-98.	1.0	15
150	Prognostic value of plasma C-reactive protein and fibrinogen determinations in patients with acute myocardial infarction treated with thrombolysis. <i>Journal of Internal Medicine</i> , 2003, 254, 244-250.	6.0	14
151	Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003114.	3.9	14
152	Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. <i>Heart</i> , 2018, 104, 1292-1299.	2.9	14
153	Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. <i>American Heart Journal</i> , 2019, 208, 65-73.	2.7	14
154	Internet-Based Cognitive Behavioral Therapy for Patients Reporting Symptoms of Anxiety and Depression After Myocardial Infarction: U-CARE Heart Randomized Controlled Trial Twelve-Month Follow-up. <i>Journal of Medical Internet Research</i> , 2021, 23, e25465.	4.3	14
155	Association between β -blocker dose and cardiovascular outcomes after myocardial infarction: insights from the SWEDEHEART registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 372-379.	1.0	14
156	<i>In-vivo</i> extravasation induces the expression of interleukin 1 receptor type 1 in human neutrophils. <i>Clinical and Experimental Immunology</i> , 2012, 168, 105-112.	2.6	13
157	Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014, 3, 246-256.	1.0	13
158	Young adulthood cognitive ability predicts statin adherence in middle-aged men after first myocardial infarction: A Swedish National Registry study. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 639-646.	1.8	11
159	Association of Factor V Leiden With Subsequent Atherothrombotic Events. <i>Circulation</i> , 2020, 142, 546-555.	1.6	11
160	Comprehensive Quality-of-Life Outcomes With Invasive Versus Conservative Management of Chronic Coronary Disease in ISCHEMIA. <i>Circulation</i> , 2022, 145, 1294-1307.	1.6	11
161	The impact of diabetes or elevated fasting blood glucose on cardiovascular prognosis in patients with stable angina pectoris. <i>Diabetic Medicine</i> , 2005, 22, 1326-1333.	2.3	10
162	Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014, 170, e59-e62.	1.7	10

#	ARTICLE	IF	CITATIONS
163	Emotional distress as a predictor of statin non-adherence among Swedish first-time myocardial infarction patients, 2006–2013. <i>Journal of Psychosomatic Research</i> , 2017, 97, 30-37.	2.6	10
164	Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. <i>American Heart Journal</i> , 2018, 196, 28-35.	2.7	10
165	Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 72, 37-43.	1.4	10
166	Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. <i>Stroke</i> , 2021, 52, 2494-2501.	2.0	10
167	<i>In vivo</i> Extravasated Human Monocytes have an Altered Expression of CD16, HLA-DR, CD86, CD36 and CXCR1. <i>Scandinavian Journal of Immunology</i> , 2009, 70, 368-376.	2.7	9
168	Psychological mediators related to clinical outcome in cognitive behavioural therapy for coronary heart disease: A sub-analysis from the SUPRIM trial. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 917-925.	1.8	9
169	Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e009609.	3.7	9
170	Temporal changes in myocardial infarction incidence rates are associated with periods of perceived psychosocial stress: A SWEDHEART national registry study. <i>American Heart Journal</i> , 2017, 191, 12-20.	2.7	9
171	Differential Index: A Simple Time Domain Heart Rate Variability Analysis with Prognostic Implications in Stable Angina Pectoris. <i>Cardiology</i> , 2008, 111, 126-133.	1.4	8
172	Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	8
173	Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, e002951.	4.8	8
174	Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	8
175	Organization of intensive cardiac care units in Europe: Results of a multinational survey. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 993-1001.	1.0	8
176	Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome. <i>Journal of Internal Medicine</i> , 2021, 290, 392-403.	6.0	8
177	Differential index, a novel graphical method for measurements of heart rate variability. <i>International Journal of Cardiology</i> , 2005, 98, 493-499.	1.7	7
178	Risk prediction in stable angina pectoris. <i>European Journal of Clinical Investigation</i> , 2013, 43, 141-151.	3.4	7
179	Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 163-173.	1.7	7
180	Cardiac rehabilitation goal attainment after myocardial infarction with versus without diabetes: A nationwide registry study. <i>International Journal of Cardiology</i> , 2019, 292, 19-24.	1.7	7

#	ARTICLE	IF	CITATIONS
181	Risk markers of incident atrial fibrillation in patients with coronary heart disease. <i>American Heart Journal</i> , 2021, 233, 92-101.	2.7	7
182	Data standards for acute coronary syndrome and percutaneous coronary intervention: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart). <i>European Heart Journal</i> , 2022, 43, 2269-2285.	2.2	7
183	Serum Neurofilament Light Chain in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 0, , .	3.7	7
184	Evaluation of various electrocardiographic criteria for left ventricular hypertrophy in patients with stable angina pectoris: influence of using modified limb electrodes. <i>Clinical Physiology</i> , 2001, 21, 196-207.	0.7	6
185	In vivo transmigrated monocytes from patients with stable coronary artery disease have a reduced expression of CD11b. <i>Clinical and Experimental Immunology</i> , 2008, 153, 196-204.	2.6	5
186	Effect of age on efficacy and safety of vorapaxar in patients with nonâ€“ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. <i>American Heart Journal</i> , 2016, 178, 176-184.	2.7	5
187	Cognitive ability, lifestyle risk factors, and two-year survival in first myocardial infarction men: A Swedish National Registry study. <i>International Journal of Cardiology</i> , 2017, 231, 13-17.	1.7	5
188	Evaluation of the Age, Biomarkers, and Clinical Historyâ€“Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , 2020, 3, e2015943.	5.9	5
189	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. <i>American Heart Journal</i> , 2020, 225, 97-107.	2.7	5
190	Designing a Web-Based Psychological Intervention for Patients With Myocardial Infarction With Nonobstructive Coronary Arteries: User-Centered Design Approach. <i>Journal of Medical Internet Research</i> , 2020, 22, e19066.	4.3	5
191	No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial. <i>International Journal of Cardiology</i> , 2014, 176, 300-302.	1.7	4
192	Pooled analysis of adverse event collection from 4 acute coronary syndrome trials. <i>American Heart Journal</i> , 2016, 174, 60-67.	2.7	4
193	Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet) Tj ETQq1 1 0.784314 rgBT /Overl	2.7	4
194	The Full Revasc (Ffr-gUidance for complete non-cuLpريت REVAScularization) Registry-based randomized clinical trial. <i>American Heart Journal</i> , 2021, 241, 92-100.	2.7	4
195	Oral anticoagulant treatment after bioprosthetic valvular intervention or valvuloplasty in patients with atrial fibrillationâ€“A SWEDEHEART study. <i>PLoS ONE</i> , 2022, 17, e0262580.	2.5	4
196	Use of Apixaban and Warfarin in Patients Undergoing Invasive Procedures: Insights From Aristotle. <i>Canadian Journal of Cardiology</i> , 2013, 29, S232-S233.	1.7	3
197	P4912Swedish cardiac rehabilitation programmes; a descriptive nationwide analysis - the perfect CR study. <i>European Heart Journal</i> , 2017, 38, .	2.2	3
198	Should we consider early de-escalation of maintenance dose of antiplatelet therapy post-ACS?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 149-150.	3.0	3

#	ARTICLE	IF	CITATIONS
199	Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions – proceedings from the CEC Summit 2018. American Heart Journal, 2022, 246, 93-104.	2.7	3
200	Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial. Circulation: Cardiovascular Interventions, 2021, , CIRCINTERVENTIONS120011035.	3.9	2
201	Independence of clinical events committees: A consensus statement from clinical research organizations. American Heart Journal, 2022, 248, 120-129.	2.7	2
202	Effects of metoprolol vs verapamil in patients with stable angina pectoris: The Angina Prognosis Study in Stockholm (APSYS). European Heart Journal, 1996, 17, 483-483.	2.2	1
203	Lessons from platelet inhibition and patient outcomes. Current Opinion in Cardiology, 2012, 27, 355-360.	1.8	1
204	Risk of events in the 30 days following a major bleed with Apixaban or Warfarin - experiences from the ARISTOTLE trial. European Heart Journal, 2013, 34, P536-P536.	2.2	1
205	Response to Letter Regarding Article, “Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation”. Circulation, 2014, 129, e21-2.	1.6	1
206	Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 155-163.	1.0	1
207	P5407 Predicting adherence to internet-delivered cognitive behaviour therapy for comorbid symptoms of depression and anxiety after myocardial infarction. European Heart Journal, 2018, 39, .	2.2	1
208	Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 Trial. Journal of the American Heart Association, 2018, 7, .	3.7	1
209	The effect of group-based cognitive behavioral therapy on inflammatory biomarkers in patients with coronary heart disease – results from the SUPRIM-trial. Upsala Journal of Medical Sciences, 2018, 123, 167-173.	0.9	1
210	Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients. Canadian Journal of Cardiology, 2019, 35, 644-652.	1.7	1
211	Self-perceived cognitive status and cognitive challenges associated with cardiac rehabilitation management: experiences of elderly myocardial infarction patients. Disability and Rehabilitation, 2022, 44, 3834-3842.	1.8	1
212	Assessing the external validity of the VALIDATE-SWEDEHEART trial. Clinical Trials, 2021, 18, 427-435.	1.6	1
213	Emotional distress in women after acute myocardial infarction – still a long way to walk. Trends in Cardiovascular Medicine, 2021, , .	4.9	1
214	Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis. Frontiers in Physiology, 0, 13, .	2.8	1
215	Soluble E-selectin is increased in concentric left ventricular hypertrophy and is related to septal wall thickness. American Journal of Hypertension, 2000, 13, S250-S251.	2.0	0
216	Improving long-term outcome after myocardial infarction. Lancet, The, 2012, 380, 1290-1291.	13.7	0

#	ARTICLE	IF	CITATIONS
217	Difference in causes of death between ticagrelor and clopidogrel in the PLATO trial. <i>European Heart Journal</i> , 2013, 34, 4536-4536.	2.2	0
218	Response to Letter: "Sorrow and cardiovascular events" TM . <i>Journal of Internal Medicine</i> , 2018, 283, 415-415.	6.0	0
219	P625 Screening multiple biomarkers for associations with major coronary events. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
220	P6249 Screening multiple biomarkers for associations with acute ischemic stroke in patients with stable coronary heart disease. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
221	2170 Screening multiple biomarkers for associations with cardiovascular death in patients with stable coronary heart disease. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
222	410 Treatment targets for systolic blood pressure are more often reached at cardiac rehabilitation centres where nurses adjust blood pressure medication doses - the Perfect-CR study. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
223	Psycho-affective pathology in adults with congenital heart disease: Important progress is being made within a challenging field. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 378-380.	1.8	0
224	Natriuretic peptides and incident atrial fibrillation. <i>American Heart Journal</i> , 2021, 241, 120.	2.7	0
225	Associations between psychosocial burden and prognostic biomarkers in patients with stable coronary heart disease " a STABILITY substudy. <i>European Heart Journal</i> , 2020, 41, .	2.2	0
226	OUP accepted manuscript. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, , .	1.0	0